Cargando…

Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption

Introduction: Granulocyte colony-stimulating factor (G-CSF) is the first line treatment for mobilization, most commonly using a regimen of daily filgrastim. The use of biosimilars can provide substantial cost savings to the health care system while delivering comparable efficacy outcomes. In 2016, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aggarwal, Vibhuti, Sabry, Waleed, Elemary, Mohamed, Bosch, Mark, Danyluk, Pat, Mondal, Prosanta, Stakiw, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161742/ https://www.ncbi.nlm.nih.gov/pubmed/33922026 http://dx.doi.org/10.3390/curroncol28030148

Ejemplares similares

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
por: Hahn, Logan, et al.
Publicado: (2021)

The Real-World Experience of the Biosimilar (Grastofil(®)) to the Reference Biologic (Neupogen(®)) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study
por: Wong, Gina, et al.
Publicado: (2022)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Biosimilar G-CSF Based Mobilization of Peripheral Blood Hematopoietic Stem Cells for Autologous and Allogeneic Stem Cell Transplantation
por: Schmitt, Michael, et al.
Publicado: (2014)

Pharmacy Travel Health Services in Canada: Experience of Early Adopters
por: Thidrickson, Doug, et al.
Publicado: (2019)

Presently available biosimilars in hematology-oncology: G-CSF
por: Gascon, Pere
Publicado: (2012)

Worldwide experience with biosimilar development
por: McCamish, Mark, et al.
Publicado: (2011)

Biosimilars Adoption: Recognizing and Removing the RoadBlocks
por: Niazi, Sarfaraz K
Publicado: (2023)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

Perioperative care of congenital adrenal hyperplasia – a disparity of physician practices in Canada
por: Nour, Munier A., et al.
Publicado: (2018)

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study
por: Moorkens, Evelien, et al.
Publicado: (2020)

The Law and Ethics of Switching from Biologic to Biosimilar in Canada
por: Murdoch, Blake, et al.
Publicado: (2020)

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
por: Bhat, Shubha, et al.
Publicado: (2020)

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
por: Müskens, Wieland D., et al.
Publicado: (2019)

Interest In and Uptake of HIV Pre-Exposure Prophylaxis (PrEP): A Cross-Sectional Study of High-Risk Patients in Western Canada
por: Enebeli, Stanley, et al.
Publicado: (2022)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data
por: McClean, Alison R., et al.
Publicado: (2022)

Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors
por: Schmitt, M, et al.
Publicado: (2013)

Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary
por: Shubow, Sophie, et al.
Publicado: (2022)

Biosimilars in inflammatory bowel disease: A review of post-marketing experience
por: Deiana, Simona, et al.
Publicado: (2017)

SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience
por: Law, Shing T., et al.
Publicado: (2019)

Skull Base Csf- Leak Closure with Autologous Fibrin Sealant
por: Poma, Salvatore, et al.
Publicado: (2021)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Endoscopic Repair of CSF Rhinorrhea: An Institutional Experience
por: Mishra, Sarita Kumari, et al.
Publicado: (2016)

Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors
por: Farhan, Roiya, et al.
Publicado: (2017)

Should Canada adopt managed access agreements in Canada for expensive drugs?
por: McPhail, Melanie, et al.
Publicado: (2023)

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone
por: Sung, Anthony D., et al.
Publicado: (2013)

Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges
por: Iyer, Rohin K., et al.
Publicado: (2018)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Lessons from International Experience with Biosimilar Implementation: An Application of the Diffusion of Innovations Model
por: Khan, Danial, et al.
Publicado: (2020)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience
por: Kurki, Pekka, et al.
Publicado: (2022)

Spanish Experience in Autologous Chondrocyte Implantation
por: Pérez-Cachafeiro, Santiago, et al.
Publicado: (2010)

Comparative Analysis of the Biosimilar and Innovative G-CSF Modulated Pathways on Umbilical Cord Blood–Derived Mononuclear Cells
por: Avila-Portillo, LM, et al.
Publicado: (2020)

Endoscopic repair of CSF rhinorrhea: experience of 44 cases
por: Filho, Bernardo Cunha Araujo, et al.
Publicado: (2015)

Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative
por: Edgar, Babette S, et al.
Publicado: (2021)

Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
por: Eplin, Dwight D., et al.
Publicado: (2019)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer
por: Krendyukov, A., et al.
Publicado: (2017)

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
por: Dellanna, Frank, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_opprapanhle2tqarbldeuvg9ct